

Table S2. Percent inhibition and seroconversion rate against SARS-CoV-2 variant of concerns

Time point	% Inhibition (median, IQR)		P-value	Seroconversion rate (n, %)		P-value
	AZD1222/ mRNA1273 (N=92)*	BNT162b2/ mRNA1273 (N=16)		AZD1222/ mRNA1273 (N=92)*	BNT162b2/ mRNA1273 (N=16)	
B.1.1.7 [Alpha]						
4-week after the 3 <sup>rd</sup> dose	97.0 (94.1, 98.1)	96.2 (95.5, 96.7)	0.097	90 (97.8)	16 (100.0)	1.000
Before the 4 <sup>th</sup> dose	84.9 (65.7, 93.3)	82.7 (68.0, 96.0)	0.551	87 (94.6)	16 (100.0)	1.000
4-week after the 4 <sup>th</sup> dose	98.5 (98.2, 98.6)	98.4 (98.1, 98.5)	0.136	89 (98.9)	16 (100.0)	1.000
B.1.351 [Beta]						
4-week after the 3 <sup>rd</sup> dose	91.8 (81.9, 95.8)	93.3 (91.6, 94.3)	0.762	88 (95.7)	16 (100.0)	1.000
Before the 4 <sup>th</sup> dose	68.3 (41.6, 78.6)	74.9 (48.0, 89.9)	0.169	80 (87.0)	16 (100.0)	0.207
4-week after the 4 <sup>th</sup> dose	98.2 (97.7, 98.4)	97.6 (97.0, 97.9)	0.002	86 (95.6)	16 (100.0)	1.000
B.1.617.2 [Delta]						
4-week after the 3 <sup>rd</sup> dose	97.9 (96.8, 98.3)	93.5 (91.7, 93.8)	<0.001	90 (97.8)	15 (93.8)	0.385
Before the 4 <sup>th</sup> dose	84.4 (61.8, 93.3)	74.1 (55.9, 92.7)	0.716	90 (97.8)	16 (100.0)	1.000
4-week after the 4 <sup>th</sup> dose	98.5 (98.2, 98.6)	98.1 (97.8, 98.5)	0.085	86 (95.6)	16 (100.0)	1.000
B.1.1.529 [Omicron]						
4-week after the 3 <sup>rd</sup> dose	62.9 (33.6, 79.6)	80.5 (62.7, 87.7)	0.046	70 (76.1)	13 (81.3)	0.759
Before the 4 <sup>th</sup> dose	12.7 (3.5, 28.8)	8.5 (5.6, 25.3)	0.795	20 (21.7)	3 (18.8)	1.000
4-week after the 4 <sup>th</sup> dose	92.9 (77.6, 96.3)	81.2 (72.9, 87.2)	0.035	84 (93.3)	15 (93.8)	1.000

\*N=90 for participants at 4 weeks after the fourth dose